Pentraxin 3 regulates synaptic function by inducing AMPA receptor clustering via ECM remodeling and β1-integrin.
Fossati G
EMBO J. 2018 Nov 5;38(1)doi: 10.15252/embj.201899529
Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis.
Ceribelli A
Clin Exp Rheumatol. 2014 Aug 15;32(6):891-7.
Prevalence of hepatitis C serum antibody in autoimmune diseases.
Agmon-Levin N
J Autoimmun. 2009 Apr 8;32(3-4):261-6. doi: 10.1016/j.jaut.2009.02.017
Post-natal cardiomyocytes can generate iPS cells with an enhanced capacity toward cardiomyogenic re-differentation.
Rizzi R
Cell Death Differ. 2012 Jan 20;19(7):1162-74. doi: 10.1038/cdd.2011.205
Prion-like Doppel gene (PRND) in the goat: genomic structure, cDNA, and polymorphisms.
Uboldi C
Mamm Genome. 2005 Dec 8;16(12):963-71.
Primary refractory and early-relapsed Hodgkin’s lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.
Carbone A
J Pathol. 2015 Jun 3;237(1):4-13. doi: 10.1002/path.4558
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
Guidetti A
Clin Cancer Res. 2014 Sep 19;20(22):5641-51. doi: 10.1158/1078-0432.CCR-14-0770
Predictors of CD34+ cell mobilization and collection in adult men with germ cell tumors: implications for the salvage treatment strategy.
Necchi A
Clin Genitourin Cancer. 2013 Nov 13;12(3):196-202.e1. doi: 10.1016/j.clgc.2013.11.021
Plerixafor ‘on demand’: results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF.
Farina L
Bone Marrow Transplant. 2013 Dec 9;49(3):453-5. doi: 10.1038/bmt.2013.193
Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
Farina L
Leuk Lymphoma. 2013 Jun 14;55(2):331-6. doi: 10.3109/10428194.2013.802783